Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases

K. Němejcová, J. Rosmusová, M. Bártů, M. Důra, I. Tichá, P. Dundr,

. 2017 ; 25 (5) : 389-396. [pub] 20161218

Language English Country United States

Document type Journal Article

BACKGROUND: Glucose transporter-1 (Glut-1) is a membrane glycoprotein that is, together with other glucose transporters, responsible for the regulation of glucose uptake. An increased expression of this protein seems to be a general feature of several malignant tumors that are able to reprogram their metabolism and switch from oxidative phosphorylation to aerobic glycolysis. METHODS: We performed comprehensive immunohistochemical analysis of Glut-1 expression in 336 endometrial samples, including tumors, nontumor lesions, and normal tissues. RESULTS: Expression of Glut-1 was found in 87% of endometrioid carcinomas (160/184 cases), 100% of serous carcinomas (29/29 cases), 100% of clear cell carcinomas (17/17 cases), 50% of polyps with atypical hyperplasia (8/16 cases), 12.5% of polyps with non-atypical hyperplasia (3/24 cases), 77% of hyperplasias with atypias (10/13 cases), 9% of hyperplasias without atypias (1/11 cases), 87% of secretory endometrium samples (13/15 cases), and in none of the nonsecretory endometrium samples (0/27 cases). In endometrioid carcinomas, Glut-1 was expressed in a marked geographical pattern. In nontumor lesions, its expression was more common in atypical hyperplasia and polyps with atypical hyperplasia compared with polyps with non-atypical hyperplasia and hyperplasias without atypia ( P = .00032). CONCLUSION: Our study confirms the high expression of Glut-1 not only in endometrioid carcinomas but also in other carcinomas of endometrium including clear cell and serous types. Glut-1 expression can be used as a surrogate marker in differential diagnosis between hyperplasia with and without atypia. Because of common Glut-1 expression in malignant tumors, therapeutic strategies influencing this protein or its signaling pathways can be beneficial.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025103
003      
CZ-PrNML
005      
20180712120243.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1066896916683510 $2 doi
035    __
$a (PubMed)28381136
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Němejcová, Kristýna $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
245    10
$a Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases / $c K. Němejcová, J. Rosmusová, M. Bártů, M. Důra, I. Tichá, P. Dundr,
520    9_
$a BACKGROUND: Glucose transporter-1 (Glut-1) is a membrane glycoprotein that is, together with other glucose transporters, responsible for the regulation of glucose uptake. An increased expression of this protein seems to be a general feature of several malignant tumors that are able to reprogram their metabolism and switch from oxidative phosphorylation to aerobic glycolysis. METHODS: We performed comprehensive immunohistochemical analysis of Glut-1 expression in 336 endometrial samples, including tumors, nontumor lesions, and normal tissues. RESULTS: Expression of Glut-1 was found in 87% of endometrioid carcinomas (160/184 cases), 100% of serous carcinomas (29/29 cases), 100% of clear cell carcinomas (17/17 cases), 50% of polyps with atypical hyperplasia (8/16 cases), 12.5% of polyps with non-atypical hyperplasia (3/24 cases), 77% of hyperplasias with atypias (10/13 cases), 9% of hyperplasias without atypias (1/11 cases), 87% of secretory endometrium samples (13/15 cases), and in none of the nonsecretory endometrium samples (0/27 cases). In endometrioid carcinomas, Glut-1 was expressed in a marked geographical pattern. In nontumor lesions, its expression was more common in atypical hyperplasia and polyps with atypical hyperplasia compared with polyps with non-atypical hyperplasia and hyperplasias without atypia ( P = .00032). CONCLUSION: Our study confirms the high expression of Glut-1 not only in endometrioid carcinomas but also in other carcinomas of endometrium including clear cell and serous types. Glut-1 expression can be used as a surrogate marker in differential diagnosis between hyperplasia with and without atypia. Because of common Glut-1 expression in malignant tumors, therapeutic strategies influencing this protein or its signaling pathways can be beneficial.
650    _2
$a adenokarcinom z jasných buněk $x diagnóza $x patologie $7 D018262
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a biopsie $7 D001706
650    _2
$a endometroidní karcinom $x diagnóza $x patologie $7 D018269
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a hyperplazie endometria $x diagnóza $x patologie $7 D004714
650    _2
$a nádory endometria $x diagnóza $x patologie $7 D016889
650    _2
$a endometrium $x patologie $7 D004717
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a přenašeč glukosy typ 1 $x metabolismus $7 D051272
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a polypy $x diagnóza $x patologie $7 D011127
650    _2
$a prekancerózy $x diagnóza $x patologie $7 D011230
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rosmusová, Jana $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Bártů, Michaela $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Důra, Miroslav $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. 2 Department of Dermatovenerology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Tichá, Ivana $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Dundr, Pavel $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
773    0_
$w MED00002376 $t International journal of surgical pathology $x 1940-2465 $g Roč. 25, č. 5 (2017), s. 389-396
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28381136 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180712120536 $b ABA008
999    __
$a ok $b bmc $g 1317234 $s 1022024
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 25 $c 5 $d 389-396 $e 20161218 $i 1940-2465 $m International journal of surgical pathology $n Int. j. surg. pathol. $x MED00002376
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...